Trial Profile
A Phase IV, single dose, openlabelled, comparative, randomized controlled study to evaluate the immunogenicity and safety of BBIL's JENVAC (Inactivate JE Vaccine) vs. Chinese SA-14- 14-2 (Live JE Vaccine) vaccine in healthy volunteers – Immunogenicity and safety following booster dose after 2 year.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Dec 2019
Price :
$35
*
At a glance
- Drugs Japanese encephalitis vaccine (Primary) ; Japanese encephalitis vaccine (Primary)
- Indications Japanese encephalitis
- Focus Pharmacodynamics
- Sponsors Bharat Biotech
- 20 Dec 2019 Results assessing persistence of immune response with an inactivated Japanese encephalitis single dose vaccine JENVAC and interchangeability with a live-attenuated vaccine published in the Journal of Infectious Diseases
- 06 Dec 2018 Status changed from not yet recruiting to completed.
- 12 Sep 2016 New trial record